News & Media
SK life science
Welcome to the news and information center for SK Life Science, Inc. (SKLSI), a CNS-focused pharmaceutical company
General business
Strategic alliance and partnership opportunities
Media inquiries and PR
Grant and investigator initiated proposals
Sponsorship requests
Medical information inquiries or report adverse events
Phone: 1-866-OKSKLSI (657-5574)
Email: medicalinfo@sklsi.com
SK life science at a glance
-
Headquarters location
PARAMUS, NJ
-
R&D Begins
1993
-
Parent Company
SK life science is a subsidiary of SK Biopharmaceuticals, Co., Ltd., and both are part of the SK Group
-
Number of employees
200+ EMPLOYEES
-
Disease Category Focus
CNS
-
Pipeline
8 compounds under clinical development
Newsroom
12/06/2022
SK Biopharmaceuticals Wins Export Award for Cenobamate
Full release12/05/2022
Seoul National University Bundang Hospital Presents Study of SK Biopharmaceuticals’ Seizure Detection Wearable Device at AES 2022
Full release12/02/2022
SK life science Presents Latest Data on XCOPRI® (cenobamate tablets) CV in Adults with Partial-Onset (Focal) Seizures at the AES 2022 Annual Meeting
Full release12/01/2022
SK Biopharmaceuticals Names Donghoon Lee, Head of Bio Investment Center of SK Inc., as New CEO
Full release11/28/2022
SK life science To Present Latest XCOPRI® (cenobamate tablets) CV Data at the American Epilepsy Society 2022 Annual Meeting
Full release11/17/2022
SK Biopharmaceuticals Named CES 2023 Innovation Awards Honoree
Full release11/14/2022
SK Biopharmaceuticals Receives Korea Drug Development Fund Investment Grant to Develop Novel Oncology Candidate, SKL27969
Full release9/12/2022
Expert Consensus Opinions Published in Neurology and Therapy Discuss Adjustment of Anti-Seizure Medication Dosing for Optimal Care
Full release8/09/2022
New Drug Filing for Cenobamate Accepted for Review in Canada and Israel
Full release7/14/2022
SK Biopharmaceuticals, Eurofarma Enter into Licensing Agreement for Cenobamate in Latin America
Full release